MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 875787-07-8
MCE 国际站:LXR-623
产品活性:LXR-623是可以渗透血脑屏障的 LXRα 部分激动剂和 LXRβ 完全激动剂,IC50 分别为24 nM 和 179 nM。
研究领域:Metabolic Enzyme/Protease | Vitamin D Related/Nuclear Receptor
作用靶点:LXR
In Vitro: LXR-623 potently kills U87EGFRvIII and GBM39 cells in vitro while completely sparing NHAs. LXR-623 also increases ABCA1 protein and decreases LDLR protein levels in all three cell lines. LXR-623 suppresses LDLR expression, increases expression of the ABCA1 efflux transporter, and induces substantial cell death in all of the GBM samples tested. LXR-623 (5 μM) also induces GBM cell death through activation of LXRβ. LXR-623 treatment of human PBMC in vitro significantly increases transcription of ABCA1 and ABCG1.
In Vivo: LXR-623 (400 mg/kg, p.o.) crosses the blood-brain barrier, induces target gene expression, and achieves therapeutic levels in GBM cells in the brain with minimal activity in the periphery. LXR-623 inhibits tumor growth, promotes tumor cell death, and prolongs the survival of mice bearing intracranial patient-derived GBMs. LXR-623 (1.5, 5 mg/kg/day) significantly reduces progression of atherosclerosis in animals compared with the placebo group. WAY-252623 (15 and 50 mg/kg) results in a significant reduction of atherosclerosis in a dose-dependent manner. WAY-252623 (20, 60, and 120 mg/kg/day, p.o.) displays neutral lipid effects in this CETP-expressing Syrian hamster. Moreover, LXR-623 (50 mg/kg) induces gene expression in rodent peripheral blood cells in rat. LXR-623 (0, 15 and 50 mg/kg) dose-dependently upregulates transcription of ABCA1 and ABCG1 in monkey whole blood cells proportional to dose.
相关产品:Clinical Compound Library Plus | Bioactive Compound Library Plus | Metabolism/Protease Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | CNS-Penetrant Compound Library | Chemical Probe Library | Lipid Metabolism Compound Library | Targeted Diversity Library | Human Metabolite Library | Nuclear Receptor Compound Library | Heterocyclic Compound Library | Rovazolac | SR9238 | Saikosaponin A | Nagilactone B | 27-Hydroxycholesterol | Gymnestrogenin | (20S)-Protopanaxatriol | FITC-GW3965 | LXRβ agonist-4 | RGX-104 | GSK3987 | 24(S)-Hydroxycholesterol | GW6340 | BMS-779788 | GSK2033 | XL041 | DMHCA | LXR antagonist 2 | SR9243 | AZ876 | T0901317 | LXRβ agonist-3 | GW3965 | Larsucosterol (trimethylamine) | LXR agonist 2 | BE1218
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。